WSJ: New Weapon in Push to Lower U.S. Biotech Drug Prices

In Europe, biosimilar uptake has been slow but is starting to ramp. An acceptance of biosimilars both in the U.S. and in Europe could present cost savings for patients, though these drugs are usually priced much higher than typical generic drugs.

Read the full article in the Wall Street Journal